Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
9,913.50 | 7,268.00 | 5,282.00 | 8,950.00 |
Receivables |
19,457.20 | 20,155.00 | 21,177.00 | 23,475.00 | |
Inventory |
12,180.40 | 13,744.00 | 14,529.00 | 16,793.00 | |
Other current assets |
271.50 | 147.00 | 214.00 | 86.00 | |
Total current assets |
62,071.30 | 55,629.00 | 54,835.00 | 64,672.00 | |
Property, Plant, Equpment (Net) |
22,316.00 | 24,675.00 | 26,540.00 | 29,286.00 | |
Long-Term Investments |
2,808.30 | 2,802.00 | 3,116.00 | 3,856.00 | |
Goodwill and Intangible Assets (Total) |
12,344.70 | 12,419.00 | 13,504.00 | 26,959.00 | |
Long Term Assets (Tax, Deferred) |
8,962.70 | 9,959.00 | 11,350.00 | 10,028.00 | |
Long-term assets (Other) |
6,432.40 | 6,992.00 | 7,231.00 | 7,482.00 | |
Total non-current assets |
52,864.10 | 56,847.00 | 61,741.00 | 77,611.00 | |
Total Assets |
114,935.40 | 112,476.00 | 116,576.00 | 142,283.00 | |
Notes Payable |
1,633.00 | 1,635.00 | 4,000.00 | — | |
Accounts Payable |
4,262.20 | 5,379.00 | 5,029.00 | 6,112.00 | |
Current Part of Debt |
— | 1,635.00 | — | 7,050.00 | |
Current Part of Taxes to Pay |
9,444.40 | — | — | — | |
Other current liabilities |
24,801.30 | 28,214.00 | 27,605.00 | 34,579.00 | |
Total current liabilities |
40,140.90 | 35,228.00 | 36,634.00 | 47,741.00 | |
Long Term Debt (Total) |
40,873.60 | 40,868.00 | 39,370.00 | 47,858.00 | |
Non-current Liabilities (Other) |
10,070.10 | 9,845.00 | 9,374.00 | 12,805.00 | |
Total non-current liabilities |
50,943.70 | 50,713.00 | 48,744.00 | 60,663.00 | |
Total liabilities |
91,084.60 | 85,941.00 | 85,378.00 | 108,404.00 | |
Additional Paid In Capital |
7,231.90 | 7,346.00 | 6,921.00 | 7,117.00 | |
Common Stock (Net) |
591.40 | 590.00 | 590.00 | 588.00 | |
Retained Earnings |
22,252.00 | 24,470.00 | 29,514.00 | 31,893.00 | |
Treasury Stock |
62.50 | — | — | — | |
Shareholders Equity (Other) |
(3,013.20) | (2,991.00) | (2,994.00) | (2,958.00) | |
Common Equity (Total) |
23,850.80 | 26,535.00 | 31,198.00 | 33,879.00 | |
Shareholders Equity (Total) |
23,850.80 | 26,535.00 | 31,198.00 | 33,879.00 | |
Shareholders Equity and Liabilities (Total) |
114,935.40 | 112,476.00 | 116,576.00 | 142,283.00 | |
Shares (Common) |
946.21 | 944.80 | 943.50 | 947.20 | |
Shareholders Equity (Tangible) |
11,506.10 | 14,116.00 | 17,694.00 | 6,920.00 | |
Net Debt |
30,960.10 | 35,235.00 | 34,088.00 | 45,958.00 | |
Total Debt |
40,873.60 | 42,503.00 | 39,370.00 | 54,908.00 |